A

Arena Pharmaceuticals Inc
F:RN3N

Watchlist Manager
Arena Pharmaceuticals Inc
F:RN3N
Watchlist
Price: 90.5 EUR 0.56% Market Closed
Market Cap: 5.6B EUR

Net Margin

-1 325 181.2%
Current
No historical data
Comparison unavailable

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 325 181.2%
=
Net Income
$-616.4m
/
Revenue
$54k

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-1 325 181.2%
=
Net Income
€-616.4m
/
Revenue
$54k

Peer Comparison

Country Company Market Cap Net
Margin
US
Arena Pharmaceuticals Inc
F:RN3N
5.6B EUR
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.8B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
177.8B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
155.1B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.1B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
85B AUD
Loading...
NL
argenx SE
XBRU:ARGX
42.4B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
47.3B USD
Loading...
No Stocks Found

Market Distribution

Lower than 100% of companies in the United States of America
Percentile
0th
Based on 11 198 companies
0th percentile
-1 325 181.2%
Low
-1 929 242.2% — 0.1%
Typical Range
0.1% — 13.7%
High
13.7% — 1 135 400%
Distribution Statistics
the United States of America
Min -1 929 242.2%
30th Percentile 0.1%
Median 6.3%
70th Percentile 13.7%
Max 1 135 400%

Arena Pharmaceuticals Inc
Glance View

Market Cap
5.6B EUR
Industry
Biotechnology

Arena Pharmaceuticals Inc., once a promising player in the biotechnology space, carved out a niche in developing novel therapies aimed at addressing unmet needs in various therapeutic areas. The company focused heavily on its proprietary drug discovery and development platform, which centered around designing and creating small molecules to activate specific receptor subtypes. This mechanism allows them to produce targeted treatments with fewer side effects, thus appealing to a market in search of more specialized therapies. At the core of Arena's portfolio was its work in the fields of cardiology, gastroenterology, and dermatology, where the company ambitiously advanced its drug candidates through meticulous research and clinical trials, hoping to bring these innovations to patients worldwide. Arena's revenue-generating strategy primarily revolved around developing these new pharmaceuticals to the point where they became attractive for partnerships or acquisitions. The company often engaged in strategic collaborations with larger pharmaceutical players, licensing its products under development, which provided crucial funding for ongoing research while retaining some rights to future revenues. This model allowed Arena to leverage the market reach and financial muscle of its partners without bearing the full brunt of commercializing a drug. This symbiotic relationship was critical for Arena’s financial stability, offering a combination of upfront payments, milestone achievements, and eventual royalties. In a constantly evolving and competitive biopharmaceutical landscape, Arena’s approach aimed to balance innovative breakthroughs with practical business acumen.

RN3N Intrinsic Value
Not Available
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-1 325 181.2%
=
Net Income
$-616.4m
/
Revenue
$54k
How has Net Margin changed over time?

Over the last 3 years, Arena Pharmaceuticals Inc’s Net Margin has decreased from -187.4% to -1 325 181.2%. During this period, it reached a low of -1 298 056.8% on Jan 31, 2022 and a high of 85.6% on Mar 31, 2019.

Back to Top